In conclusion, our meta-analysis demonstrates that L-C treatment in CHF patients may improve clinical symptoms and cardiac function and decrease serum levels of BNP and NT-proBNP and has good tolerance. The gene discussed is NPPB; the disease is congestive heart failure.